array(3) { ["company_details"]=> array(13) { ["name"]=> string(25) "ROCHE DIAGNOSTICS LIMITED" ["slug"]=> string(34) "ef866-gb-roche-diagnostics-limited" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/5ce04174-8fff-4069-9bd1-2ef80ada854c" ["description"]=> string(1583) "Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com/global/en Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation" ["address_street"]=> string(14) "Charles Avenue" ["address_place"]=> string(12) "BURGESS HILL" ["address_region"]=> NULL ["founding_date"]=> string(10) "1956-09-14" ["website_domain"]=> string(9) "roche.com" ["website_url"]=> string(29) "https://diagnostics.roche.com" ["industry_codes"]=> array(1) { [0]=> string(43) "Business Services, Not Elsewhere Classified" } ["employee_count"]=> int(658) ["article_count"]=> int(3438) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(65) "Roche reimagines the office: A wellness oasis for the digital age" ["snippet_en"]=> string(299) "The office is dead. Long live the office, but not as we knew it. The past two years of remote work have fundamentally reshaped our understanding of office space. Gone are the days of sterile cubicles; modern offices must cater to the evolving needs of a hybrid workforce, fostering collaboration and" ["url"]=> string(98) "https://www.hrkatha.com/features/roche-reimagines-the-office-a-wellness-oasis-for-the-digital-age/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/a79ad15c-1d85-40d1-a758-f0635b0993d3" ["source"]=> string(11) "hrkatha.com" ["publication_date"]=> string(10) "2024-04-01" ["categories"]=> array(2) { [0]=> string(14) "Work from Home" [1]=> string(25) "Business Model Resilience" } } [1]=> array(7) { ["title_en"]=> string(71) "Lonza buys Roche factory in the USA for $1.2 billion - SWI swissinfo.ch" ["snippet_en"]=> string(275) "Lonza is taking over the Roche subsidiary Genentech's plant in Vacaville in the USA. The pharmaceutical supplier is investing $1.2 billion for this and wants to continue investing. An additional $500 million will be invested in the expansion, as Lonza announced on Wednesday." ["url"]=> string(107) "https://www.swissinfo.ch/ger/lonza-kauft-f%C3%BCr-1%2C2-milliarden-us-dollar-roche-werk-in-den-usa/73949257" ["image_url"]=> string(78) "https://images.businessradar.com/articles/6268e55f-20f9-44fb-b69c-3fa2b8746831" ["source"]=> string(12) "swissinfo.ch" ["publication_date"]=> string(10) "2024-03-20" ["categories"]=> array(4) { [0]=> string(25) "Business Model Resilience" [1]=> string(18) "General Investment" [2]=> string(11) "Acquisition" [3]=> string(18) "Expansion & Growth" } } [2]=> array(7) { ["title_en"]=> string(54) "Roche factory in Penzberg: Group invests in Nonnenwald" ["snippet_en"]=> string(129) "The Roche Group can look back on a good 2023 financial year. The company is investing 600 million euros in its plant in Penzberg." ["url"]=> string(122) "https://www.merkur.de/lokales/dasgelbeblatt/oberland/roche-werk-in-penzberg-konzern-investiert-im-nonnenwald-92840461.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/658ae5f2-fd1c-440e-a20f-bd5e2973e089" ["source"]=> string(9) "merkur.de" ["publication_date"]=> string(10) "2024-02-19" ["categories"]=> array(6) { [0]=> string(18) "General Investment" [1]=> string(18) "Financial Distress" [2]=> string(20) "Business Development" [3]=> string(19) "Investment Requests" [4]=> string(18) "Expansion & Growth" [5]=> string(25) "Business Model Resilience" } } [3]=> array(7) { ["title_en"]=> string(94) "Despite Roche's sharp COVID sales decline, eye drug Vabysmo powers major revenue win, CEO says" ["snippet_en"]=> string(289) "As Roche CEO Thomas Schinecker sees it, the Swiss pharma made a “major achievement” in 2023. Despite a sharp decline in COVID-related sales, the company was able to grow overall revenues | As Roche CEO Thomas Schinecker sees it, the Swiss pharma made a “major achievement” in 2023." ["url"]=> string(115) "https://www.fiercepharma.com/pharma/vabysmo-skyrockets-roche-grows-through-covid-products-decline-major-achievement" ["image_url"]=> string(78) "https://images.businessradar.com/articles/94ba243b-0371-45fa-a08d-bfb2f16da580" ["source"]=> string(16) "fiercepharma.com" ["publication_date"]=> string(10) "2024-02-01" ["categories"]=> array(4) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(31) "Financial Update/Profit Warning" [2]=> string(8) "Epidemic" [3]=> string(25) "Business Model Resilience" } } [4]=> array(7) { ["title_en"]=> string(82) "Roche looks back on a weak year in 2023 and only dares to make a cautious forecast" ["snippet_en"]=> string(183) "BASEL (dpa-AFX) - The slump in sales in the Corona business and the strong competition from copycat products have had a negative impact on the pharmaceutical company Roche in the past" ["url"]=> string(143) "https://www.t-online.de/finanzen/boerse/ticker/roche-blickt-auf-schwaches-jahr-2023-zurueck-und-wagt-nur-vorsichtige-prognose/0DB082000C7F9111/" ["image_url"]=> NULL ["source"]=> string(11) "t-online.de" ["publication_date"]=> string(10) "2024-02-01" ["categories"]=> array(3) { [0]=> string(8) "Epidemic" [1]=> string(25) "Business Model Resilience" [2]=> string(11) "Competition" } } [5]=> array(7) { ["title_en"]=> string(77) "The Future of Medical Equipment is Total Lab Automation and Digital Solutions" ["snippet_en"]=> string(160) "The constantly increasing demand for health services in Malta, both in the public as well as the private sector, requires ongoing investment not only to serve c" ["url"]=> string(95) "https://cde.news/the-future-of-medical-equipment-is-total-lab-automation-and-digital-solutions/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/3cd43f0c-da22-4632-b4ce-dc3b876a6970" ["source"]=> string(8) "cde.news" ["publication_date"]=> string(10) "2024-01-30" ["categories"]=> array(1) { [0]=> string(25) "Business Model Resilience" } } [6]=> array(7) { ["title_en"]=> string(65) "Roche completes acquisition of Carmot Therapeutics - TipRanks.com" ["snippet_en"]=> string(167) "Carmot Therapeutics announced that its acquisition by the Roche Group has been completed. Having successfully completed its acquisition of Carmot, Roche obtains acc..." ["url"]=> string(88) "https://www.tipranks.com/news/the-fly/roche-completes-acquisition-of-carmot-therapeutics" ["image_url"]=> NULL ["source"]=> string(12) "tipranks.com" ["publication_date"]=> string(10) "2024-01-29" ["categories"]=> array(4) { [0]=> string(25) "Business Model Resilience" [1]=> string(18) "Expansion & Growth" [2]=> string(11) "Acquisition" [3]=> string(21) "Competitive Behaviour" } } [7]=> array(7) { ["title_en"]=> string(116) "J&J acquisition of Ambrx bolsters cancer ADC portfolio amidst big pharma’s growing investment trend - BioVoiceNews" ["snippet_en"]=> string(112) "Prior to the announced J&J deal, last year alone saw 155 deals struck for the modality, 14 of which were in M&A." ["url"]=> string(123) "https://biovoicenews.com/jj-acquisition-of-ambrx-bolsters-cancer-adc-portfolio-amidst-big-pharmas-growing-investment-trend/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/421affd8-3bb8-4c72-8f84-1a720fdba0bc" ["source"]=> string(16) "biovoicenews.com" ["publication_date"]=> string(10) "2024-01-10" ["categories"]=> array(5) { [0]=> string(25) "Business Model Resilience" [1]=> string(11) "Acquisition" [2]=> string(6) "Merger" [3]=> string(15) "Deals & Tenders" [4]=> string(15) "Market Movement" } } [8]=> array(7) { ["title_en"]=> string(64) "Roche to fold struggling diabetes business into diagnostics unit" ["snippet_en"]=> string(126) "In 2017, the company considered options for the business including a sale, people close to the deliberations said at the time." ["url"]=> string(128) "https://www.financialexpress.com/healthcare/diagnostic/roche-to-fold-struggling-diabetes-business-into-diagnostics-unit/3353273/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/d96dc3a4-4b12-42b6-b194-c7a1f2582e45" ["source"]=> string(20) "financialexpress.com" ["publication_date"]=> string(10) "2024-01-02" ["categories"]=> array(3) { [0]=> string(20) "Business Development" [1]=> string(22) "Business Restructuring" [2]=> string(25) "Business Model Resilience" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(217) } [1]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(204) } [2]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(192) } [3]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(156) } [4]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(153) } [5]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(148) } [6]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(137) } [7]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(136) } [8]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(111) } [9]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(105) } [10]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(102) } [11]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(97) } [12]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(92) } [13]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(89) } [14]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(86) } [15]=> array(2) { ["name"]=> string(25) "Business Model Resilience" ["count"]=> int(69) } [16]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(65) } [17]=> array(2) { ["name"]=> string(13) "Data Security" ["count"]=> int(64) } [18]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(63) } [19]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(49) } [20]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(42) } [21]=> array(2) { ["name"]=> string(12) "Going Public" ["count"]=> int(40) } [22]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(40) } [23]=> array(2) { ["name"]=> string(19) "Economic Conditions" ["count"]=> int(38) } [24]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(33) } [25]=> array(2) { ["name"]=> string(12) "Staff hiring" ["count"]=> int(33) } [26]=> array(2) { ["name"]=> string(10) "New Market" ["count"]=> int(32) } [27]=> array(2) { ["name"]=> string(20) "Business Development" ["count"]=> int(32) } [28]=> array(2) { ["name"]=> string(7) "Layoffs" ["count"]=> int(32) } [29]=> array(2) { ["name"]=> string(16) "Customer Welfare" ["count"]=> int(32) } } } ef866-gb-roche-diagnostics-limited